GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (OSTO:ALZCUR) » Definitions » Deferred Policy Acquisition Costs

AlzeCure Pharma AB (OSTO:ALZCUR) Deferred Policy Acquisition Costs


View and export this data going back to 2018. Start your Free Trial

What is AlzeCure Pharma AB Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


AlzeCure Pharma AB Business Description

Industry
Traded in Other Exchanges
Address
Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.